{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:25:28Z","timestamp":1785583528454,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100021092","name":"University of Yamanashi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100021092","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT), particularly in patients with a high HokUS-10 score after starting treatment. Tolvaptan sodium phosphate (TSP) is a novel intravenous aquaretic agent used to treat refractory fluid retention in congestive heart failure (CHF). Here, we report the successful treatment of severe post-HSCT SOS with refractory fluid retention and CHF using TSP plus defibrotide. A 22-year-old man with relapsed acute lymphoblastic leukemia underwent unrelated peripheral blood stem cell transplantation and developed SOS on day 13. Despite defibrotide therapy and standard management, fluid retention rapidly progressed, resulting in an 18.3% increase in body weight on day 21 and a high HokUS-10 score (10\/13 points). TSP (16\u00a0mg) administered to treat the CHF immediately induced adequate urine output. Continued TSP treatment (8\u00a0mg\/day) resulted in sustained diuresis and a return to baseline body weight on day 33. The only significant adverse event observed during the 5\u00a0weeks of TSP treatment was transient hypernatremia (148\u00a0mEq\/L). Defibrotide was discontinued on day 72 because the HokUS-10 score had decreased to 1 point. Our experience suggests the utility of TSP in controlling refractory fluid retention due to post-HSCT SOS.<\/jats:p>","DOI":"10.1007\/s12185-025-04022-z","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T06:50:15Z","timestamp":1749192615000},"page":"611-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Utility of tolvaptan sodium phosphate for refractory fluid retention in post-transplant sinusoidal obstruction syndrome"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-1281","authenticated-orcid":false,"given":"Koshi","family":"Akahane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minori","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Goi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"7","key":"4022_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","volume":"58","author":"M Mohty","year":"2023","unstructured":"Mohty M, Malard F, Alaskar AS, Aljurf M, Arat M, Bader P, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 2023;58(7):749\u201354. https:\/\/doi.org\/10.1038\/s41409-023-01992-8.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4022_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","volume":"55","author":"M Mohty","year":"2020","unstructured":"Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020;55(3):485\u201395. https:\/\/doi.org\/10.1038\/s41409-019-0705-z.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"4022_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.15267","volume":"181","author":"NA Kernan","year":"2018","unstructured":"Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Br J Haematol. 2018;181(6):816\u201327. https:\/\/doi.org\/10.1111\/bjh.15267.","journal-title":"Br J Haematol"},{"issue":"13","key":"4022_CR4","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656\u201365. https:\/\/doi.org\/10.1182\/blood-2015-10-676924.","journal-title":"Blood"},{"issue":"6","key":"4022_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50(6):781\u20139. https:\/\/doi.org\/10.1038\/bmt.2015.52.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"4022_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bjh.13215","volume":"168","author":"E Carreras","year":"2015","unstructured":"Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2015;168(4):481\u201391. https:\/\/doi.org\/10.1111\/bjh.13215.","journal-title":"Br J Haematol"},{"issue":"4","key":"4022_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00228-011-1006-7","volume":"67","author":"N Gassanov","year":"2011","unstructured":"Gassanov N, Semmo N, Semmo M, Nia AM, Fuhr U, Er F. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol. 2011;67(4):333\u201346. https:\/\/doi.org\/10.1007\/s00228-011-1006-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"4022_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s12185-012-1248-x","volume":"97","author":"K Yakushijin","year":"2013","unstructured":"Yakushijin K, Yamamoto K, Kurata K, Miyata Y, Kakiuchi S, Tomioka H, et al. Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation. Int J Hematol. 2013;97(2):284\u20136. https:\/\/doi.org\/10.1007\/s12185-012-1248-x.","journal-title":"Int J Hematol"},{"issue":"4","key":"4022_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1253\/circj.CJ-21-0430","volume":"86","author":"N Sato","year":"2022","unstructured":"Sato N, Uno S, Yamasaki Y, Hirano T, Kim S, Investigators OPC. Pharmacokinetics, pharmacodynamics, efficacy, and safety of OPC-61815, a prodrug of tolvaptan for intravenous administration, in patients with congestive heart failure\u2014a phase II, multicenter, double-blind, randomized, active-controlled trial. Circ J. 2022;86(4):699\u2013708. https:\/\/doi.org\/10.1253\/circj.CJ-21-0430.","journal-title":"Circ J"},{"issue":"5","key":"4022_CR10","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1002\/ehf2.14021","volume":"9","author":"N Sato","year":"2022","unstructured":"Sato N, Uno S, Kurita Y, Kim S, Investigators O-H. Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure. ESC Heart Fail. 2022;9(5):3275\u201386. https:\/\/doi.org\/10.1002\/ehf2.14021.","journal-title":"ESC Heart Fail"},{"issue":"9","key":"4022_CR11","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.bbmt.2018.05.025","volume":"24","author":"M Nishida","year":"2018","unstructured":"Nishida M, Kahata K, Hayase E, Shigematsu A, Sato M, Kudo Y, et al. Novel ultrasonographic scoring system of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(9):1896\u2013900. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.025.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4022_CR12","doi-asserted-by":"publisher","first-page":"17374","DOI":"10.1038\/s41598-023-43806-3","volume":"13","author":"S Shiratori","year":"2023","unstructured":"Shiratori S, Okada K, Sugita J, Nishida M, Iwai T, Ota S, et al. HokUS-10 scoring system predicts the treatment outcome for sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. Sci Rep. 2023;13(1):17374. https:\/\/doi.org\/10.1038\/s41598-023-43806-3.","journal-title":"Sci Rep"},{"issue":"4","key":"4022_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jccase.2022.12.009","volume":"27","author":"M Nakamura","year":"2023","unstructured":"Nakamura M, Imamura T, Wakakuri E, Onoda H, Ushijima R, Kinugawa K. Initial clinical experience of intravenous tolvaptan sodium phosphate in patients with congestive heart failure. J Cardiol Cases. 2023;27(4):176\u20139. https:\/\/doi.org\/10.1016\/j.jccase.2022.12.009.","journal-title":"J Cardiol Cases"},{"key":"4022_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030720","author":"M Nakamura","year":"2024","unstructured":"Nakamura M, Imamura T, Kinugawa K. Preliminary report of intravenous tolvaptan sodium phosphate (Samtas((R))) treatment in decompensated heart failure. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13030720.","journal-title":"J Clin Med"},{"issue":"7","key":"4022_CR15","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1253\/circj.CJ-21-0926","volume":"86","author":"K Kinugawa","year":"2022","unstructured":"Kinugawa K, Nakata E, Hirano T, Kim S. Tolerability of the intravenously administered tolvaptan prodrug, OPC-61815, in patients with congestive heart failure who have difficulty with, or are incapable of, oral intake (TRITON-HF)\u2014a phase III, multicenter, open-label trial. Circ J. 2022;86(7):1068\u201378. https:\/\/doi.org\/10.1253\/circj.CJ-21-0926.","journal-title":"Circ J"},{"issue":"4","key":"4022_CR16","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3390\/jcm3041276","volume":"3","author":"PR Bhatt","year":"2014","unstructured":"Bhatt PR, McNeely EB, Lin TE, Adams KF, Patterson JH. Review of tolvaptan\u2019s pharmacokinetic and pharmacodynamic properties and drug interactions. J Clin Med. 2014;3(4):1276\u201390. https:\/\/doi.org\/10.3390\/jcm3041276.","journal-title":"J Clin Med"},{"issue":"4","key":"4022_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","volume":"73","author":"SE Shoaf","year":"2012","unstructured":"Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br J Clin Pharmacol. 2012;73(4):579\u201387. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04114.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"4022_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","volume":"41","author":"U Christians","year":"2002","unstructured":"Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41(11):813\u201351. https:\/\/doi.org\/10.2165\/00003088-200241110-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"4022_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0090-9556(25)08793-8","volume":"20","author":"M Sattler","year":"1992","unstructured":"Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20(5):753\u201361.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"4022_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"PJ Neuvonen","year":"2006","unstructured":"Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565\u201381. https:\/\/doi.org\/10.1016\/j.clpt.2006.09.003.","journal-title":"Clin Pharmacol Ther"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04022-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T06:52:11Z","timestamp":1758955931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04022-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4022"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04022-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}